US20160168200A1 - Immunotherapy against several tumors, such as lung cancer, including nsclc - Google Patents

Immunotherapy against several tumors, such as lung cancer, including nsclc Download PDF

Info

Publication number
US20160168200A1
US20160168200A1 US14/908,078 US201414908078A US2016168200A1 US 20160168200 A1 US20160168200 A1 US 20160168200A1 US 201414908078 A US201414908078 A US 201414908078A US 2016168200 A1 US2016168200 A1 US 2016168200A1
Authority
US
United States
Prior art keywords
cell
peptide
seq
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/908,078
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Jens FRITSCHE
Colette SONG
Harpreet Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160168200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Priority to US14/908,078 priority Critical patent/US20160168200A1/en
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRITSCHE, JENS, SONG, Colette, SINGH, HARPREET, WEINSCHENK, TONI, WALTER, STEFFEN
Publication of US20160168200A1 publication Critical patent/US20160168200A1/en
Priority to US15/357,838 priority patent/US10071148B2/en
Priority to US15/639,058 priority patent/US9943579B2/en
Priority to US15/639,165 priority patent/US20170320913A1/en
Priority to US16/100,858 priority patent/US10160786B1/en
Priority to US16/274,491 priority patent/US10323065B1/en
Priority to US16/283,528 priority patent/US10316062B1/en
Priority to US16/283,540 priority patent/US10316063B1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
US14/908,078 2013-08-05 2014-08-04 Immunotherapy against several tumors, such as lung cancer, including nsclc Abandoned US20160168200A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/908,078 US20160168200A1 (en) 2013-08-05 2014-08-04 Immunotherapy against several tumors, such as lung cancer, including nsclc
US15/357,838 US10071148B2 (en) 2013-08-05 2016-11-21 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US15/639,058 US9943579B2 (en) 2013-08-05 2017-06-30 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US15/639,165 US20170320913A1 (en) 2013-08-05 2017-06-30 Immunotherapy against several tumors, such as lung cancer, including nsclc
US16/100,858 US10160786B1 (en) 2013-08-05 2018-08-10 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US16/274,491 US10323065B1 (en) 2013-08-05 2019-02-13 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US16/283,540 US10316063B1 (en) 2013-08-05 2019-02-22 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US16/283,528 US10316062B1 (en) 2013-08-05 2019-02-22 Immunotherapy against several tumors, such as lung cancer, including NSCLC

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GB1313987.8 2013-08-05
GB1403297.3 2014-02-25
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
US14/908,078 US20160168200A1 (en) 2013-08-05 2014-08-04 Immunotherapy against several tumors, such as lung cancer, including nsclc
PCT/EP2014/066755 WO2015018805A1 (en) 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/066755 A-371-Of-International WO2015018805A1 (en) 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/357,838 Continuation US10071148B2 (en) 2013-08-05 2016-11-21 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US15/639,165 Continuation US20170320913A1 (en) 2013-08-05 2017-06-30 Immunotherapy against several tumors, such as lung cancer, including nsclc

Publications (1)

Publication Number Publication Date
US20160168200A1 true US20160168200A1 (en) 2016-06-16

Family

ID=52460698

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/908,078 Abandoned US20160168200A1 (en) 2013-08-05 2014-08-04 Immunotherapy against several tumors, such as lung cancer, including nsclc
US15/357,838 Active US10071148B2 (en) 2013-08-05 2016-11-21 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US15/639,058 Active US9943579B2 (en) 2013-08-05 2017-06-30 Immunotherapy against several tumors, such as lung cancer, including NSCLC

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/357,838 Active US10071148B2 (en) 2013-08-05 2016-11-21 Immunotherapy against several tumors, such as lung cancer, including NSCLC
US15/639,058 Active US9943579B2 (en) 2013-08-05 2017-06-30 Immunotherapy against several tumors, such as lung cancer, including NSCLC

Country Status (29)

Country Link
US (3) US20160168200A1 (zh)
EP (10) EP3616712A1 (zh)
JP (1) JP2016527293A (zh)
KR (9) KR102213552B1 (zh)
CN (1) CN105377290B (zh)
AU (10) AU2014304544B2 (zh)
BR (1) BR112016000810A2 (zh)
CA (4) CA3020939C (zh)
CL (1) CL2016000227A1 (zh)
CR (4) CR20210464A (zh)
DK (2) DK3456339T3 (zh)
EA (1) EA035362B1 (zh)
ES (1) ES2764406T3 (zh)
HK (1) HK1222121A1 (zh)
HU (1) HUE047079T2 (zh)
IL (1) IL243788B (zh)
LT (1) LT3030255T (zh)
MX (1) MX2016001426A (zh)
NZ (2) NZ714163A (zh)
PE (3) PE20201284A1 (zh)
PH (1) PH12015502638A1 (zh)
PL (1) PL3030255T3 (zh)
PT (1) PT3030255T (zh)
RS (1) RS59861B1 (zh)
SG (4) SG10202002608WA (zh)
SI (1) SI3030255T1 (zh)
TW (10) TWI777195B (zh)
UA (1) UA122661C2 (zh)
WO (1) WO2015018805A1 (zh)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10055540B2 (en) 2015-12-16 2018-08-21 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
WO2018170313A1 (en) * 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
WO2018200921A1 (en) * 2017-04-28 2018-11-01 Chung Shan Medical University Peptides for cancer treatment
US10377803B1 (en) 2017-07-07 2019-08-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10472402B2 (en) 2017-07-07 2019-11-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10501522B2 (en) 2015-03-27 2019-12-10 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US10526389B2 (en) 2015-04-24 2020-01-07 Immatics Biotechnologies Gmbh Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10532091B1 (en) 2015-08-05 2020-01-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10653761B2 (en) 2015-12-10 2020-05-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US10654904B2 (en) 2015-10-05 2020-05-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10695411B2 (en) 2015-08-28 2020-06-30 Immatics Biotechnologies Gmbh Method of treating with a peptide
US10695373B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
CN111808908A (zh) * 2020-06-18 2020-10-23 华中科技大学同济医学院附属协和医院 一种促脑胶质瘤耐药的gaMSCs亚群的检测方法
US10835586B2 (en) 2015-03-31 2020-11-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
US10899806B2 (en) 2015-10-05 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10898561B2 (en) 2015-03-17 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
US11065314B2 (en) * 2015-12-22 2021-07-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CN113150115A (zh) * 2018-05-16 2021-07-23 伊玛提克斯生物技术有限公司 用于抗癌免疫治疗的肽
US11117951B2 (en) 2016-05-25 2021-09-14 Immatics Biotechnologies Gmbh Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11161880B2 (en) * 2013-08-05 2021-11-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors, such as lung cancer, including NSCLC
US11230581B2 (en) 2015-07-01 2022-01-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11264117B2 (en) 2017-10-10 2022-03-01 Gritstone Bio, Inc. Neoantigen identification using hotspots
US11365235B2 (en) 2015-03-27 2022-06-21 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11541107B2 (en) 2015-08-28 2023-01-03 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US11597752B2 (en) 2015-05-06 2023-03-07 Immatics Biotechnologies Gmbh Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US11826410B2 (en) 2015-12-11 2023-11-28 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11897936B2 (en) 2016-05-25 2024-02-13 Immatics Biotechnologies Gmbh Peptides, combination of peptides as targets and for use in immunotherapy
US11912748B2 (en) 2015-07-01 2024-02-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
PE20180253A1 (es) * 2015-06-19 2018-02-02 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer
CR20170579A (es) * 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
US20170136108A1 (en) 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
KR20170049024A (ko) * 2015-10-28 2017-05-10 숙명여자대학교산학협력단 ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법
US10383896B2 (en) 2015-12-11 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG10202110335PA (en) * 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
PE20181897A1 (es) * 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10868749B2 (en) * 2016-07-26 2020-12-15 Motorola Mobility Llc Method and apparatus for discovering neighborhood awareness networking devices based on presence
HRP20211677T1 (hr) * 2016-08-17 2022-02-18 Immatics Biotechnologies Gmbh T-stanični receptori i imunološka terapija koja koristi iste
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US11612643B2 (en) * 2016-09-30 2023-03-28 Genoimmune Therapeutics Co, , Ltd. Col14A1-derived tumor antigen polypeptide and use thereof
WO2018102613A2 (en) * 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN110944660A (zh) * 2017-04-10 2020-03-31 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
KR20210013105A (ko) * 2018-05-23 2021-02-03 그릿스톤 온콜로지, 인코포레이티드 공유 항원
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
CA3135618A1 (en) * 2019-04-02 2020-10-08 The General Hospital Corporation Methods to enhance t cell regeneration
CN111020024A (zh) * 2019-12-05 2020-04-17 复旦大学附属眼耳鼻喉科医院 Tlr9的应用
WO2022125339A2 (en) * 2020-12-07 2022-06-16 The Trustees Of Indiana University Methods to sensitize cancer cells to immune attack using atractylenolide i
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
CN113969264B (zh) * 2021-11-29 2023-12-08 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN115125203B (zh) * 2022-07-08 2023-10-27 珠海贝索细胞科学技术有限公司 一种Th2细胞体外培养方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
ATE472601T1 (de) 2000-03-27 2010-07-15 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1442295B1 (en) * 2001-08-13 2008-07-30 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
WO2004018633A2 (en) * 2002-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Abca13 nucleic acids and proteins, and uses thereof
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100535326B1 (ko) * 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
DK1760088T3 (da) 2005-09-05 2008-06-09 Immatics Biotechnologies Gmbh Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
EA200801865A1 (ru) * 2006-02-22 2009-02-27 Филоджен Спа Опухолевые маркеры сосудов
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2178557B1 (en) * 2007-07-27 2017-03-01 Immatics Biotechnologies GmbH Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
AU2008320987B2 (en) * 2007-11-13 2014-04-17 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against TL1A
US7996174B2 (en) * 2007-12-18 2011-08-09 Teradyne, Inc. Disk drive testing
AU2009221915A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2009126271A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
AU2009287163B2 (en) * 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
JP5892701B2 (ja) * 2009-05-15 2016-03-23 パシフィック エッジ バイオテクノロジー リミティド 胃ガンの検出用マーカー
US20110033516A1 (en) * 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281223B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. Detection of fuse re-growth in a microprocessor
US20120270769A1 (en) * 2009-10-23 2012-10-25 Marsault Eric Methods of using macrocyclic inhibitors of serine protease enzymes
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101378919B1 (ko) * 2010-01-28 2014-04-14 포항공과대학교 산학협력단 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
US9028810B2 (en) * 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Cited By (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866517B2 (en) 2013-08-05 2024-01-09 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11814446B2 (en) 2013-08-05 2023-11-14 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11161880B2 (en) * 2013-08-05 2021-11-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors, such as lung cancer, including NSCLC
US11161878B2 (en) * 2013-08-05 2021-11-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11161879B2 (en) * 2013-08-05 2021-11-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors, such as lung cancer, including NSCLC
US11161877B2 (en) * 2013-08-05 2021-11-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11939400B2 (en) 2013-08-05 2024-03-26 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11939401B2 (en) 2013-08-05 2024-03-26 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US11859017B2 (en) 2013-08-05 2024-01-02 Immatics Biotechnologies Gmbh Immunotherapy against several tumors including lung cancer
US10898561B2 (en) 2015-03-17 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US11365235B2 (en) 2015-03-27 2022-06-21 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11407808B2 (en) 2015-03-27 2022-08-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11466072B2 (en) 2015-03-27 2022-10-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11897934B2 (en) 2015-03-27 2024-02-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11440947B2 (en) 2015-03-27 2022-09-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11365234B2 (en) 2015-03-27 2022-06-21 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11407807B2 (en) 2015-03-27 2022-08-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11407810B2 (en) 2015-03-27 2022-08-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US10501522B2 (en) 2015-03-27 2019-12-10 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11873329B2 (en) 2015-03-27 2024-01-16 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11407809B2 (en) 2015-03-27 2022-08-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11965013B2 (en) 2015-03-27 2024-04-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11459371B2 (en) 2015-03-27 2022-10-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11434274B2 (en) 2015-03-27 2022-09-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11434273B2 (en) 2015-03-27 2022-09-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US11702460B2 (en) 2015-03-27 2023-07-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various tumors
US10835586B2 (en) 2015-03-31 2020-11-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
US11938176B2 (en) 2015-03-31 2024-03-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
US10925948B2 (en) 2015-04-24 2021-02-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US11027002B2 (en) 2015-04-24 2021-06-08 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US11071773B2 (en) 2015-04-24 2021-07-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10898559B2 (en) 2015-04-24 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US11324812B2 (en) 2015-04-24 2022-05-10 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10662233B2 (en) 2015-04-24 2020-05-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10898560B2 (en) 2015-04-24 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10577402B2 (en) 2015-04-24 2020-03-03 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10550167B2 (en) 2015-04-24 2020-02-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US10526389B2 (en) 2015-04-24 2020-01-07 Immatics Biotechnologies Gmbh Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
US11597752B2 (en) 2015-05-06 2023-03-07 Immatics Biotechnologies Gmbh Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US11912748B2 (en) 2015-07-01 2024-02-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11230581B2 (en) 2015-07-01 2022-01-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11912749B2 (en) 2015-07-01 2024-02-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US10532091B1 (en) 2015-08-05 2020-01-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US11826409B2 (en) 2015-08-05 2023-11-28 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US11786584B2 (en) 2015-08-05 2023-10-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US11957742B2 (en) 2015-08-28 2024-04-16 Immatics Biotechnologies Gmbh Method for treating non-small lung cancer with a population of activated T cells
US11744882B2 (en) 2015-08-28 2023-09-05 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US11065316B2 (en) 2015-08-28 2021-07-20 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunother[[r]]apeutic treatment of various cancers
US11541107B2 (en) 2015-08-28 2023-01-03 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US10695411B2 (en) 2015-08-28 2020-06-30 Immatics Biotechnologies Gmbh Method of treating with a peptide
US11793866B2 (en) 2015-08-28 2023-10-24 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US11975058B2 (en) 2015-08-28 2024-05-07 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US11547750B2 (en) 2015-08-28 2023-01-10 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment hepatocellular carcinoma
US11559572B2 (en) 2015-08-28 2023-01-24 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US11951160B2 (en) 2015-08-28 2024-04-09 Immatics Biotechnologies Gmbh Peptides and T cells for use in immunotherapeutic treatment of various cancers
US10898558B2 (en) 2015-08-28 2021-01-26 Immatics Biotechnologies Gmbh Method of treating with a peptide
US11576954B2 (en) 2015-08-28 2023-02-14 Immatics Biotechnologies Gmbh Method for treating non-small lung cancer with a population of activated cells
US11111280B2 (en) 2015-10-05 2021-09-07 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10899806B2 (en) 2015-10-05 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10654904B2 (en) 2015-10-05 2020-05-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US11905319B2 (en) 2015-10-05 2024-02-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US10722566B2 (en) 2015-12-10 2020-07-28 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US10653761B2 (en) 2015-12-10 2020-05-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US10653762B2 (en) 2015-12-10 2020-05-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US11833194B2 (en) 2015-12-11 2023-12-05 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
US11826410B2 (en) 2015-12-11 2023-11-28 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
US11183286B2 (en) 2015-12-16 2021-11-23 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
US10055540B2 (en) 2015-12-16 2018-08-21 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US10847253B2 (en) 2015-12-16 2020-11-24 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US10847252B2 (en) 2015-12-16 2020-11-24 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US11065314B2 (en) * 2015-12-22 2021-07-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
US11897935B2 (en) 2016-05-25 2024-02-13 Immatics Biotechnologies Gmbh Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11117951B2 (en) 2016-05-25 2021-09-14 Immatics Biotechnologies Gmbh Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11897936B2 (en) 2016-05-25 2024-02-13 Immatics Biotechnologies Gmbh Peptides, combination of peptides as targets and for use in immunotherapy
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
WO2018170313A1 (en) * 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
TWI740034B (zh) * 2017-04-28 2021-09-21 中山醫學大學 治療癌症之肽
US11591368B2 (en) 2017-04-28 2023-02-28 Chung Shan Medical University Peptides for cancer treatment
WO2018200921A1 (en) * 2017-04-28 2018-11-01 Chung Shan Medical University Peptides for cancer treatment
US10472402B2 (en) 2017-07-07 2019-11-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10435449B2 (en) 2017-07-07 2019-10-08 Inmatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10450357B2 (en) 2017-07-07 2019-10-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10392427B1 (en) 2017-07-07 2019-08-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10385105B1 (en) 2017-07-07 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10377803B1 (en) 2017-07-07 2019-08-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US11459366B2 (en) 2017-07-07 2022-10-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10597434B2 (en) 2017-07-07 2020-03-24 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10836806B2 (en) 2017-07-07 2020-11-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US11866473B2 (en) 2017-07-07 2024-01-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US10711048B2 (en) 2017-07-07 2020-07-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
US11264117B2 (en) 2017-10-10 2022-03-01 Gritstone Bio, Inc. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US10813953B2 (en) 2018-02-21 2020-10-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10888582B2 (en) 2018-02-21 2021-01-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11141437B2 (en) 2018-02-21 2021-10-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers
US11147839B2 (en) 2018-02-21 2021-10-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11147838B2 (en) 2018-02-21 2021-10-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11154576B2 (en) 2018-02-21 2021-10-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11065279B2 (en) 2018-02-21 2021-07-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11058727B2 (en) 2018-02-21 2021-07-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11052114B2 (en) 2018-02-21 2021-07-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11052113B2 (en) 2018-02-21 2021-07-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11179418B2 (en) 2018-02-21 2021-11-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11040069B2 (en) 2018-02-21 2021-06-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11197892B2 (en) 2018-02-21 2021-12-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11033585B2 (en) 2018-02-21 2021-06-15 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11033583B2 (en) 2018-02-21 2021-06-15 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11026977B2 (en) 2018-02-21 2021-06-08 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11020434B2 (en) 2018-02-21 2021-06-01 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11357797B2 (en) 2018-02-21 2022-06-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11020433B2 (en) 2018-02-21 2021-06-01 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11013766B2 (en) 2018-02-21 2021-05-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11369636B2 (en) 2018-02-21 2022-06-28 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11376281B2 (en) 2018-02-21 2022-07-05 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11013768B2 (en) 2018-02-21 2021-05-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11013769B2 (en) 2018-02-21 2021-05-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10993964B2 (en) 2018-02-21 2021-05-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10993962B2 (en) 2018-02-21 2021-05-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10905720B2 (en) 2018-02-21 2021-02-02 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10905719B2 (en) 2018-02-21 2021-02-02 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10898519B2 (en) 2018-02-21 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10898518B2 (en) 2018-02-21 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10894064B2 (en) 2018-02-21 2021-01-19 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10888584B2 (en) 2018-02-21 2021-01-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10888583B2 (en) 2018-02-21 2021-01-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10888586B2 (en) 2018-02-21 2021-01-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10888585B2 (en) 2018-02-21 2021-01-12 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11103535B2 (en) 2018-02-21 2021-08-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10874695B2 (en) 2018-02-21 2020-12-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10874696B2 (en) 2018-02-21 2020-12-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869895B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11779606B2 (en) 2018-02-21 2023-10-10 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869891B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869890B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11801264B2 (en) 2018-02-21 2023-10-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869893B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869896B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869894B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10869892B2 (en) 2018-02-21 2020-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10799537B2 (en) 2018-02-21 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10792308B2 (en) 2018-02-21 2020-10-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10695373B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10792307B2 (en) 2018-02-21 2020-10-06 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10780123B2 (en) 2018-02-21 2020-09-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10780124B2 (en) 2018-02-21 2020-09-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10780122B2 (en) 2018-02-21 2020-09-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10772915B2 (en) 2018-02-21 2020-09-15 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10751369B2 (en) 2018-02-21 2020-08-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10709738B2 (en) 2018-02-21 2020-07-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10709737B2 (en) 2018-02-21 2020-07-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11918607B2 (en) 2018-02-21 2024-03-05 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10709736B2 (en) 2018-02-21 2020-07-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10702553B2 (en) 2018-02-21 2020-07-07 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10695375B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US11951132B2 (en) 2018-02-21 2024-04-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10695374B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10695376B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
US10695377B2 (en) 2018-02-21 2020-06-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
CN113150115A (zh) * 2018-05-16 2021-07-23 伊玛提克斯生物技术有限公司 用于抗癌免疫治疗的肽
WO2021016109A1 (en) * 2019-07-19 2021-01-28 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN111808908A (zh) * 2020-06-18 2020-10-23 华中科技大学同济医学院附属协和医院 一种促脑胶质瘤耐药的gaMSCs亚群的检测方法

Also Published As

Publication number Publication date
TWI777196B (zh) 2022-09-11
AU2018200389A1 (en) 2018-02-08
CA2912500C (en) 2021-08-24
US9943579B2 (en) 2018-04-17
PL3030255T3 (pl) 2020-05-18
KR102213556B1 (ko) 2021-02-05
EP3616710A1 (en) 2020-03-04
TWI777197B (zh) 2022-09-11
CA3073394A1 (en) 2015-02-12
SG11201510580UA (en) 2016-02-26
CA3073256A1 (en) 2015-02-12
AU2020220043A1 (en) 2020-09-03
AU2020220039A1 (en) 2020-09-03
DK3456339T3 (da) 2021-12-06
KR20160038889A (ko) 2016-04-07
TW202041519A (zh) 2020-11-16
UA122661C2 (uk) 2020-12-28
US20170202937A1 (en) 2017-07-20
KR102317816B1 (ko) 2021-10-26
KR102213552B1 (ko) 2021-02-05
PE20201284A1 (es) 2020-11-24
RS59861B1 (sr) 2020-03-31
CN105377290B (zh) 2019-09-03
EP3616708A1 (en) 2020-03-04
TW202041521A (zh) 2020-11-16
EP3030255B1 (en) 2019-10-09
IL243788A0 (en) 2016-04-21
MX2016001426A (es) 2016-05-05
SI3030255T1 (sl) 2020-02-28
TW202041522A (zh) 2020-11-16
EP3616712A1 (en) 2020-03-04
CN105377290A (zh) 2016-03-02
TWI777198B (zh) 2022-09-11
SG10201802399WA (en) 2018-04-27
WO2015018805A1 (en) 2015-02-12
EP3616711A1 (en) 2020-03-04
AU2018200389B2 (en) 2020-07-16
SG10202002608WA (en) 2020-04-29
NZ733168A (en) 2020-04-24
AU2020220042B2 (en) 2021-11-25
US20170319675A1 (en) 2017-11-09
CR20210464A (es) 2021-10-26
KR20200078681A (ko) 2020-07-01
TWI777194B (zh) 2022-09-11
DK3030255T3 (da) 2020-01-20
TW202041516A (zh) 2020-11-16
KR20200122418A (ko) 2020-10-27
EP3456339B1 (en) 2021-10-20
AU2020220043B2 (en) 2021-11-25
TW202041520A (zh) 2020-11-16
US10071148B2 (en) 2018-09-11
HK1222121A1 (zh) 2017-06-23
CA3020939C (en) 2023-01-03
AU2020220044A1 (en) 2020-09-03
SG10202002612PA (en) 2020-05-28
KR102213554B1 (ko) 2021-02-05
KR102217680B1 (ko) 2021-02-18
KR102213551B1 (ko) 2021-02-05
CR20200139A (es) 2020-09-02
EP3613427A1 (en) 2020-02-26
KR20210008169A (ko) 2021-01-20
AU2020220041A1 (en) 2020-09-03
EP3030255A1 (en) 2016-06-15
TWI714869B (zh) 2021-01-01
PH12015502638A1 (en) 2016-03-07
KR20200123266A (ko) 2020-10-28
TW202041515A (zh) 2020-11-16
TW201900669A (zh) 2019-01-01
TWI819228B (zh) 2023-10-21
AU2020220040A1 (en) 2020-09-03
TWI776192B (zh) 2022-09-01
AU2020220040B2 (en) 2021-11-25
KR102211542B1 (ko) 2021-02-02
AU2020220042A1 (en) 2020-09-03
CL2016000227A1 (es) 2016-08-05
AU2020220038B2 (en) 2021-11-25
AU2020220041B2 (en) 2021-11-25
EP3578196A1 (en) 2019-12-11
LT3030255T (lt) 2020-01-27
EP3616707A1 (en) 2020-03-04
AU2020220045A1 (en) 2020-09-03
KR102098327B1 (ko) 2020-04-08
TW201506043A (zh) 2015-02-16
EP3616709A1 (en) 2020-03-04
CA3020939A1 (en) 2015-02-12
AU2020220038A1 (en) 2020-09-03
JP2016527293A (ja) 2016-09-08
NZ714163A (en) 2017-07-28
PE20181538A1 (es) 2018-09-26
EA201690016A1 (ru) 2016-05-31
AU2020220045B2 (en) 2021-11-25
AU2020220044B2 (en) 2021-11-25
ES2764406T3 (es) 2020-06-03
KR20180107295A (ko) 2018-10-01
AU2020220039B2 (en) 2021-05-20
HUE047079T2 (hu) 2020-04-28
TW202041517A (zh) 2020-11-16
TWI777195B (zh) 2022-09-11
AU2014304544A1 (en) 2015-12-03
KR20200122419A (ko) 2020-10-27
KR20200122417A (ko) 2020-10-27
KR20180105754A (ko) 2018-09-28
TWI775117B (zh) 2022-08-21
CA2912500A1 (en) 2015-02-12
EP3456339A2 (en) 2019-03-20
EP3456339A3 (en) 2019-03-27
EA035362B1 (ru) 2020-06-02
AU2014304544B2 (en) 2017-10-26
KR102098329B1 (ko) 2020-04-09
TW202041518A (zh) 2020-11-16
CR20160018A (es) 2016-06-08
CR20180508A (es) 2019-02-27
PT3030255T (pt) 2020-01-15
TWI636065B (zh) 2018-09-21
PE20160717A1 (es) 2016-07-21
IL243788B (en) 2019-10-31
BR112016000810A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
US9943579B2 (en) Immunotherapy against several tumors, such as lung cancer, including NSCLC
US11859017B2 (en) Immunotherapy against several tumors including lung cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMMATICS BIOTECHNOLOGIES GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEINSCHENK, TONI;WALTER, STEFFEN;FRITSCHE, JENS;AND OTHERS;SIGNING DATES FROM 20160129 TO 20160208;REEL/FRAME:037989/0174

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION